ArticleMaterials today. Bio2024

Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.

Chengyan Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.